European indapamide market is estimated to grow significantly at a CAGR of around 3.2% during the forecast period. Europe has a huge economic burden of heart-related diseases such as CVD, CHD, stroke, and other heart diseases. Europe region including UK, Spain, Germany, France, Italy, Sweden, and other EU countries have a huge pool of CVD patients that creates scope for the growth of the indapamide market. The European Stroke Organization (ESO) and Stroke Alliance for Europe (SAFE) published European Stroke Action Plan (ESAP) in May 2018. The aim of the plan is to set a roadmap and goals for the treatment of stroke in Europe by 2030.Indapamide is used as a preventive treatment of stroke in combination with perindopril, therefore, the growing stroke cases in the region further contribute to the growth of the market during the forecast period.
A full report of European Indapamide Market is available at: https://www.omrglobal.com/industry-reports/european-indapamide-market
The European indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-indapamide-market
The companies which are contributing to the growth of the European indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
European Indapamide Market- Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
European Indapamide Market– Segment by Country
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
